ACCU-MAB NEWS RELEASE
April 24, 2001
ALTACHEM PHARMA MANUFACTURES AND DELIVERS FIRST
ACCU-MABTM DIAGNOSTIC KITS
EDMONTON – Warren Jackson, President and CEO of Altachem Pharma Ltd.., an emerging leader in the pharmaceutical industry, announced today that the Company has completed the manufacture and delivery of the first batch of Accu-MabTM diagnostic kits, since purchasing the assets of the diagnostic business unit of Cytovax Biotechnologies Inc. on February 27, 2001.
On April 10, 2001, the Company shipped Accu-MabTM diagnostic kits to 29 different Public Health laboratories and children’s hospitals in the United States and to several facilities in Canada, Chile and Spain. The Company has also received inquiries about the kits from France, Germany, Korea and China.
Accu-MabTM Plus is a device used in the identification and differentiation of Bordetella pertussis (whopping cough, a severe respiratory infection which can cause serious symptoms in young children) and Bordetella parapertussis. The product is classified as a medical device by HPB (Health Canada) and the FDA (Food and Drug Administration of the United States). The Bordetella pertussis/parapertussis is a reportable disease in both Canada and the United States.
"The Accu-MabTM device is highly specific for Bordetella pertussis and Bordetella parapertussis," said Mr. Jackson. "The product is used mainly by public health laboratories and children’s hospitals."
Altachem Pharma Ltd. invests in, develops, manufactures and distributes pharmaceutical products in Canada and internationally. The Company is certified compliant with internationally recognized quality system standards, ISO 9002:1994, ISO 13488 and EN 46002.
Altachem’s primary operating components include a Manufacturing Division, a Proprietary Drugs Division and a Joint Venture registered in the People’s Republic of China to manufacture and distribute pharmaceutical products.
For information on the purchase of the Accu-MabTM device, contact:
Lindsay Smith
Altachem Pharma Ltd.
Tel. 780-448-1400 ext. 222
Fax. 780-416-0324
E-mail: sales@altachempharma.com
For additional information, contact:
Rogers Andrews, Investor Relations
Altachem Pharma Ltd.
Tel. 486-8331 ext. 331
Fax. 780-448-1436
Toll Free: 1-877-502-5939
E-mail: roger@altachempharma.com
Web: altachempharma.com
Don Bain, Vice President
McManus Elliott Communications
Tel. 416-979-8300
Fax. 416-979-8638
E-mail: don@mcmanuselliott.com
This release may include "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For information purposes only, from sources deemed to by reliable. |
